LOTEL GEL

Indications

• Osteoporosis
• Paget's disease of bone
• Prevention of bone loss associated with corticosteroid therapy

Dosage

Children: Refer to specific dosing guidelines in clinical references or the BNF for Children.

Adults: Refer to specific dosing guidelines in clinical references or the BNF.

Mechanism of action

Etabonate acts by inhibiting osteoclast-mediated bone resorption. It binds to hydroxyapatite in the bone, leading to decreased recruitment and activity of osteoclasts. This results in a reduction of bone turnover, allowing for increased bone mass and improved structural integrity.

Pharmacodynamics

Etabonate exhibits its effects through the inhibition of the mevalonate pathway, which is crucial for the synthesis of cholesterol and other isoprenoids necessary for osteoclast function. The drug ultimately leads to a decrease in the number and activity of osteoclasts, thereby reducing bone resorption and promoting a net gain in bone density.

Pharmacokinetics

Etabonate is poorly absorbed from the gastrointestinal tract, with bioavailability significantly affected by food and other medications. Once absorbed, it is distributed to bone tissue where it remains for extended periods. The elimination half-life is prolonged due to its affinity for bone, and it is primarily excreted unchanged in the urine. Renal function has a significant impact on the drug's clearance.

Pregnancy

There is no well-established safety data for the use of etabonate in pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

The excretion of etabonate in human milk is not known. Caution should be exercised when administering this drug to a nursing mother.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Indications

• Allergic conjunctivitis
• Post-operative inflammation
• Inflammatory ocular conditions

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

The short term effects of corticosteroids like loteprednol include decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Loteprednol binds to the glucocorticoid receptor, mediating changes in gene expression that result in multiple downstream effects over hours to days. Lower doses exert anti-inflammatory effects, while higher doses can lead to immunosuppression.

Pharmacodynamics

Loteprednol, as a corticosteroid, binds to the glucocorticoid receptor which inhibits pro-inflammatory signals while promoting anti-inflammatory signals. It has a wide therapeutic window, allowing for doses that can be multiples of the body's natural production. Caution is advised regarding the potential for hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections in patients receiving corticosteroids.

Pharmacokinetics

The pharmacokinetics of loteprednol involve its absorption into ocular tissues, where it exerts its therapeutic effects locally. The drug is metabolized in the liver, and its elimination half-life may vary depending on the formulation and route of administration. Specific data on the absorption, distribution, metabolism, and excretion of loteprednol are not provided.

Adverse effects

• Increased intraocular pressure
• Cataract formation
• Delayed wound healing
• Ocular irritation or discomfort

Precautions

• Use with caution in patients with a history of herpes simplex keratitis
• Monitor intraocular pressure regularly
• Consider potential systemic effects with prolonged use

Pregnancy

Loteprednol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult the relevant guidelines.

Breast-feeding

It is not known whether loteprednol is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Ophthalmic suspension
• Ophthalmic ointment

Mechanism of action

The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.

Pharmacodynamics

Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.